Inclusion Criteria:

- All patients must sign an informed consent indicating that they are aware of the
investigational nature of this study; patients must also have signed an authorization
for the release of their protected health information

- Patients must have histologically confirmed adenocarcinoma of the prostate recurring
after local therapy (radical prostatectomy and/or radiation therapy) as evidenced by
rising serum PSA

- Prostate-Specific Antigen (PSA) Doubling Time (PSADT) =< 12 months after local
therapy (prostatectomy and/or definitive radiation) as determined by linear
regression of all available PSA values within 6 months of initiation of androgen
ablation (for patients who underwent prostatectomy, at least one PSA measurement of
>= 1.0 ng/mL; for patients who underwent radiation, at least one PSA measurement of
>= 3.0 ng/mL and >= 150% postradiation nadir)

- No evidence of metastasis as determined by bone scan or computed tomography (CT) scan

- Initiation of Androgen Ablation of less than 8 weeks' duration prior to study entry
is permitted

- Leukocytes ≥ 3,000/mcl

- Absolute neutrophil count ≥ 1,000/mcl

- Hemoglobin ≥ 8.0g/dl

- Eligibility level for hemoglobin may be reached by transfusion

- Platelet count >= 100,000/μL

- Total bilirubin ≤1.5 X laboratory ULN

- AST and/or ALT ≤ 3 X laboratory ULN

- Creatinine ≤ 1.5 X laboratory ULN OR calculated creatinine clearance ≥ 60 ml/min/1.73
m^2 for patients w/creatinine levels above the laboratory ULN

- Serum cholesterol level < 350 mg/dl

- Triglyceride level < 300mg/dl

- ECOG performance status 0, 1 or 2

- The effects of Temsirolimus on the developing human fetus are unknown; for this
reason men must agree to use contraception from the time of study enrollment
continuing for the duration of study participation

- Patients must be registered in the MDACC institutional database prior to treatment
with study drug

- PSA < 40 ng/ml

Exclusion Criteria:

- Patients with histologic variants other than adenocarcinoma in the primary tumor

- Patients may not be receiving any other investigational agents

- Patients may not be receiving concomitant immunotherapy or immunosuppressive therapy

- Patients may not have received prior systemic treatment for prostate cancer (other
than no more than 3 months of prior treatment with androgen ablation in neoadjuvant
and/or adjuvant setting and at least a year must have elapsed since last
administration) unless initiation of Androgen Ablation of less than 8 weeks' duration
prior to study entry is permitted

- Patient with uncontrolled intercurrent illness including, but not limited to ongoing
or active infection requiring parenteral therapy on day 1 of protocol treatment,
symptomatic congestive heart failure resulting in a resting O2 saturation of < 92% on
room air, unstable angina pectoris, myocardial infarction within the previous 6
months, or use of ongoing maintenance therapy for life-threatening ventricular
arrhythmia, known pulmonary hypertension or pneumonitis

- Patients in a severely compromised immunological state, including being positive for
the human immunodeficiency virus (HIV) due to possible pharmacokinetic interactions
with HAART therapy

- Patients diagnosed with acute or chronic hepatitis B or C

- Patients using immunosuppressive agents, including intravenous corticosteroids,
within 3 weeks of study entry

- Patients must not have a history of any other cancer (except nonmelanoma skin
cancer), unless in complete remission and off of all therapy for that disease for a
minimum of 3 years